The XIV Congress of the Polish Diabetes Association held in Lódź at the end of May was a great success. Polfa Tarchomin was a silver sponsor of the event.
For the first time in history Polfa Tarchomin S.A. got involved in an event on such a large scale and became a Silver Sponsor of the event. Congress participation allowed for the successful creation of a company image, showing the Polfa Trachomin is a partner of physicians in gaining access to the latest medical expertise to enable to treat their patients in compliance with the best world standards.
The Congress of the Polish Diabetes Association is organised not only for diabetologists, but also for GPs and cardiologists, as diabetes is a multidisciplinary issue. Patients do not only suffer “high sugar level”, but the metabolic disorders they experience are also associated with hyperlipidemia (high cholesterol) and hypertension, which, in combination with diabetes, makes a deadly combination leading to the rapid development of atherosclerosis, heart attacks and strokes. This deadly mix of disorders is referred to as metabolic syndrome. All these elements were first linked in the 80s by Professor Markolf Hanefeld from the Dresden University; he also named and described the syndrome. We were therefore pleased and proud that we could invite the Congress participants to enjoy a lecture by Professor Hanefeld who has accepted our invitation and a satellite session titled “Insulin therapy in Type II diabetes: Who for? When? How long?”
Another speaker invited by Polfa was Professor Józef Drzewoski – Head of the Department of Internal Diseases, Diabetology and Clinical Pharmacology, Medical University of Łódź, President of the Polish Society of Metabolic Diseases and the author of hundreds of scientific papers and several books in the field of metabolic disorders, particularly diabetes.
Such distinguished speakers aroused great interest among the congress participants; over 400 of them participated in the lectures. This figure is noteworthy as three other satellite sessions of the competitors were held at the same time. In his speech Professor Hanefeld presented a number of strong arguments based on the results of clinical studies focussed on the question why the insulin therapy should or should not be applied in patients with type II diabetes. Our company was particularly pleased that both speakers emphasised the highest global quality of human insulin produced by Polfa Tarchomin S.A. and pointed out the fact that newer and more expensive insulin analogues offered by foreign competitors are not at all more beneficial to the patient.
Besides the mentioned session, we had the opportunity to meet virtually all congress participants at our new exhibition booth where company’s representatives addressed all questions relating to the Polhumin application and checked the knowledge about diabetes and Polhumin in the multimedia quiz.